FDA Archives | Page 9 of 9

Home / Posts tagged FDA (Page 9)

RedHill Biopharma and IntelGenx Announce RIZAPORT® Commercialization Term Sheet with Pharmatronic Co. for Korea

TEL-AVIV, Israel, Sept. 21 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a Canadian drug delivery company focused on oral [...]

Woodbridge International Closes Immunostics – Boditech Med Deal

NEW HAVEN, Conn., May 9 (Korea Bizwire) — Woodbridge International, a global mergers and acquisitions firm, is pleased to announce the acquisition of its client Immunostics, Inc. by Boditech Med, Inc. Based in Ocean, New Jersey, Immunostics develops, manufactures and sells FDA-approved microbiological, serological and immunological diagnostic kits and reagents. The Company’s flagship products test [...]

RedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection

TEL-AVIV, Israel, Apr. 18 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has concluded a positive Type B Meeting with the U.S. Food [...]

Ekso GT™ Robotic Exoskeleton Cleared by FDA for Use with Stroke and Spinal Cord Injury Patients

RICHMOND, Calif., Apr. 4 (Korea Bizwire) — Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries [...]

Rapid Micro Biosystems Announces the Commercial Availability of the Growth Direct™ MultiTest System

LOWELL, Mass., Sept. 1 (Korea Bizwire) — Rapid Micro Biosystems, the provider of automated, rapid, non-destructive detection and enumeration technologies in microbiology, today announced the continued expansion of the Growth Direct™ product line with the launch of the Growth Direct MultiTest System. The technology automates the incubation, detection, and results reporting steps for bioburden, environmental [...]

ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients

RI-002 Phase III Study Achieves Primary Endpoint RAMSEY, N.J., Dec. 3 (Korea Bizwire) — ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its lead product candidate RI-002 has demonstrated positive Phase III results and [...]